Clinical outcomes of pharmacological therapies for heart failure in Black vs. White populations: a meta-analysis of randomized controlled trials of heart failure treatment
Black individuals with HF appeared to obtain a greater benefit of HHF risk reduction from SGLT2i and less benefit for mortality from beta-blockers compared to their White counterparts.
Authors
- Shao‐Hsuan Chang (ORCID: https://orcid.org/0000-0003-2545-743X)
- Jiang Bian (ORCID: https://orcid.org/0000-0002-2238-5429)
- Mustafa M. Ahmed (ORCID: https://orcid.org/0000-0003-2781-7873)
- Yujia Li (ORCID: https://orcid.org/0000-0002-5655-5254)
- Jingchuan Guo (ORCID: https://orcid.org/0000-0001-9799-2592)
- Huilin Tang (ORCID: https://orcid.org/0000-0002-5814-6657)
- Wenxi Huang (ORCID: https://orcid.org/0000-0002-8237-6401)
- Wei‐Han Chen (ORCID: https://orcid.org/0000-0001-8545-6127)
- Stephen E. Kimmel
Institutions
- University of Florida (US)
- Florida College (US)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-06-30
- DOI
- https://doi.org/10.3389/fcvm.2025.1482311
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pharmaceutical Research and Manufacturers of America Foundation